One of the great challenges to developing new drugs for cancer treatment is to select therapeutic targets whose activity is critical to the survival of particular types of cancer cells. Much more challenging is the identification of those molecules, or more often, those networks of molecules, whose dysregulation plays a critical role in the pathological properties of the cancer cell. Targeting these critical molecules with novel drugs or biologic reagents is one of the most promising ways to develop new treatments for disease.
Speakers Include:
Chandra Bartholomuesz, M.D., Ph.D.
Robert Bast, M.D.
Bingbing Dai, Ph.D.
Benjamin Lukose, B.Sc.
Arvind Rao, Ph.D.
Naoto Ueno, M.D., Ph.D.